Sun Pharma Advanced Research Co. Ltd. · NSE:SPARC
Sun Pharma Advanced Research — Corporate Update (January 2024)
9 slides from Sun Pharma Advanced Research's corporate update, Jan 6, 2024
Slide 1: Exchange filing cover letter: Investor Presentation
SPARC/Sec/SE/2023-24/077 January 06, 2024 National Stock Exchange of India Ltd., BSE Limited, Exchange Plaza, 5th Floor, Market Operations Dept. Plot No. C/1, G Block, P. J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 051. Mumbai - 400 001. Scrip Symbol: SPARC Scrip Code:
Slide 2: Signature of Company Secretary
Yours faithfully, For Sun Pharma Advanced Research Company Ltd. KAJAL Digitally signed by KAJAL DAMANIA DN: cn=KAJAL DAMANIA, o=SPIL.COM, ou=SPIL, DAMANIA email=kajal.damania@sparcmail.com , c=IN Date: 2024.01.06 14:12:42 +05'30' Kajal Damania Company Secretary and Compliance Officer
Slide 3: Investor update
Investor update 06 January, 2024 BSE:532872 NSE: SPARC BLOOMBERG: SPADV@IN REUTERS: 1 SPRC.BO CIN:L73100GJ2006PLC047837 SPARC © 2024
Slide 4: Forward-looking statements
Forward-looking statements This presentation and its contents should not be distributed, published or reproduced, in whole or part, or disclosed by recipients directly or indirectly to any other person. Any failure to comply with these restrictions may constitute a violation of applicable laws. Acco
Slide 5: Vodobatinib for Parkinson's disease: Study status updates
Vodobatinib for Parkinson’s disease Study status updates Vodobatinib PoC study – PROSEEK is fully enrolled – 513 patients; Interim analysis is planned for ~ 85% of patients enrolled in Part 1 of the study (441 patients); Broader organization will continue to be blinded to the outcome of the study to
Slide 6: Vodobatinib for Parkinson's disease: Near term priorities
Vodobatinib for Parkinson’s disease Near term priorities Immediate priorities post PROSEEK read-out include the following: End of Phase 2 consultation with the USFDA and other regulatory agencies; Completion of the Long Term Extension study; Initiation of Phase 3 studies globally; Finalization and e
Slide 7: Vodobatinib for Parkinson's disease: Program risks
Vodobatinib for Parkinson’s disease Program risks Vodbatinib addresses a significant unmet need, but translation risks remain: Translatability of animal models of Parkinson’s Disease; Lack of validated target engagement markers; Reproducibility of clinical Proof of Concept studies; and PROSEEK clini
Slide 8: Vodobatinib for Parkinson's disease: Market risks
Vodobatinib for Parkinson’s disease Market risks Biotechs’ approaching key data events attract significant speculative activity: Exploitative or uninformed attempts to manufacture positive or negative outlook; Significant risks in speculative trading involving uncertain data events; and Investors wh
Slide 9: Trademark notice
The SPARC Logo is a trademarks of Sun Pharma Advanced Research Company Ltd . In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material is for use during an oral presentation; it is not a complete reco
Sun Pharma Advanced Research Company — Corporate Update (January 2024) on 6ix